<DOC>
	<DOCNO>NCT02864563</DOCNO>
	<brief_summary>Neuroblastoma ( NB ) characterize wide heterogeneity clinical presentation evolution . Recent retrospective study reveal CGH-array overall genomic pattern important prognostic marker might take account treatment stratification . This protocol deal prospective analysis genomic profile establish CGH-array tumor sample obtain diagnosis patient NB France , obtain genomic profile able determine prognostic impact various protocol treatment . The objective study well therapeutic stratification future trial , study protocols treatment .</brief_summary>
	<brief_title>Pan-genome Analysis Neuroblastoma Comparative Genomic Hybridization Correlation With Pathology Diagnostic Prognostic Classification</brief_title>
	<detailed_description>After diagnosis Neuroblastoma ( NB ) Ganglioneuroblastoma : - Frozen tumor sample ( cell content ≥60 % ) must send genomic profile determination CGH-array , - Blood sample diagnosis must send evaluate MYCN amplification plasma , - In case NB MYCN amplification , blood sample treatment follow-up must send .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<criteria>1 . Neuroblastoma Ganglioneuroblastoma define INSS criterion ( Brodeur et al . 1993 ) 2 . Age &lt; 18 year 3 . Availability tumoral sample obtain diagnosis , prior chemotherapy tumor cell content ≥ 60 % 4 . Inclusion 4 month follow diagnosis 5 . All patient treat French center ( SFCE ) Neuroblastic tumour , include participate national international protocol . 7 . Written inform consent 8 . Patients French Social Security compliance French law relate biomedical research . 1 . Chemotherapy radiotherapy take tumour sample 2 . Refusal parent legal representative</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>